AEON Biopharma
Developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | N/A | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (25 %) | - | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1502 %) | (879 %) | - | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 5151 % | (1307 %) | - | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 143 % | 291 % | - | - | - | - |
Source: Company filings or news article
Related Content
AEON BioPharma is a pioneering company in the medical use of botulinum toxins, focusing on enhancing patient lives through innovative therapies. The company operates in the biopharmaceutical market, specializing in the development and commercialization of therapeutic applications for botulinum toxin type A. AEON BioPharma's core product, ABP 450, is a prabotulinumtoxinA injection that causes chemical denervation of muscles, leading to a localized reduction in muscle activity. This product is designed to treat various medical conditions that result in pain and decreased functionality due to muscle disorders.
AEON BioPharma serves a diverse range of clients, including healthcare providers, medical institutions, and patients suffering from muscle-related medical conditions. The company's business model revolves around research and development, clinical trials, regulatory approvals, and the commercialization of its botulinum toxin products. Revenue is generated through the sale of ABP 450 injections and potentially through partnerships and licensing agreements with other pharmaceutical companies.
The company is committed to innovation, compassion, and agility, constantly seeking new ways to improve existing therapies and introduce groundbreaking treatments. AEON BioPharma's mission is to transform the therapeutic landscape of botulinum toxins, making a significant impact on patient care and quality of life.
Keywords: botulinum toxin, ABP 450, muscle activity reduction, biopharmaceutical, therapeutic applications, healthcare providers, medical institutions, patient care, innovation, clinical trials.